Adaptimmune Free Cash Flow vs Begin Period Cash Flow Analysis

ADAP Stock

USD 0.65 0.03 4.84%

Adaptimmune Therapeutics financial indicator trend analysis is way more than just evaluating Adaptimmune Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adaptimmune Therapeutics is a good investment. Please check the relationship between Adaptimmune Therapeutics Free Cash Flow and its Begin Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Free Cash Flow vs Begin Period Cash Flow

Free Cash Flow vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adaptimmune Therapeutics Free Cash Flow account and Begin Period Cash Flow. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Adaptimmune Therapeutics' Free Cash Flow and Begin Period Cash Flow is -0.69. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Adaptimmune Therapeutics Plc, assuming nothing else is changed. The correlation between historical values of Adaptimmune Therapeutics' Free Cash Flow and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Adaptimmune Therapeutics Plc are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Free Cash Flow i.e., Adaptimmune Therapeutics' Free Cash Flow and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.69

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Adaptimmune Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adaptimmune Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

As of 01/05/2025, Selling General Administrative is likely to grow to about 86.7 M, while Tax Provision is likely to drop slightly above 832.7 K.

	2022	2023	2024	2025 (projected)
Net Interest Income	1.5M	6.0M	6.9M	7.2M
Interest Income	1.5M	6.0M	6.9M	7.2M

Net Interest Income Interest Income

Adaptimmune Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Common Stock Shares Outstanding	Short Term Debt	Property Plant Equipment	Net Tangible Assets
Total Assets		0.3	0.61	0.72	0.62	-0.39	-0.62	0.61	0.64	0.63	0.36	0.95	0.21	0.84	0.58	0.69	0.72	0.61	0.46	0.98	0.72	0.17	-0.78	0.12	0.53	0.79
Other Current Liab	0.3		0.74	-0.1	0.5	0.17	-0.52	0.26	-0.03	0.5	-0.06	0.14	0.27	0.41	0.43	0.43	0.49	0.51	0.43	0.21	0.4	0.05	0.02	-0.05	0.45	-0.05
Total Current Liabilities	0.61	0.74		0.07	0.73	-0.19	-0.72	0.71	0.44	0.73	0.12	0.41	0.5	0.7	0.66	0.5	0.71	0.76	0.67	0.51	0.7	0.1	-0.38	0.03	0.73	0.16
Total Stockholder Equity	0.72	-0.1	0.07		0.01	-0.23	0.04	0.25	0.47	0.06	0.63	0.84	-0.35	0.33	-0.13	0.33	0.12	-0.1	-0.16	0.78	0.15	0.5	-0.76	0.31	-0.08	0.99
Property Plant And Equipment Net	0.62	0.5	0.73	0.01		-0.07	-0.96	0.69	0.25	0.99	0.1	0.37	0.69	0.94	0.85	0.67	0.97	0.89	0.93	0.49	0.95	-0.27	-0.44	-0.35	0.96	0.14
Net Debt	-0.39	0.17	-0.19	-0.23	-0.07		0.14	-0.14	-0.87	-0.02	0.08	-0.46	-0.29	-0.24	-0.32	0.1	-0.14	-0.31	-0.17	-0.45	-0.27	-0.22	0.46	-0.71	-0.12	-0.25
Retained Earnings	-0.62	-0.52	-0.72	0.04	-0.96	0.14		-0.6	-0.26	-0.93	0.08	-0.38	-0.69	-0.91	-0.93	-0.67	-0.97	-0.93	-0.9	-0.51	-0.92	0.39	0.31	0.34	-0.91	-0.09
Accounts Payable	0.61	0.26	0.71	0.25	0.69	-0.14	-0.6		0.36	0.73	0.39	0.43	0.34	0.7	0.5	0.54	0.66	0.57	0.59	0.51	0.65	0.05	-0.55	-0.07	0.63	0.34
Cash	0.64	-0.03	0.44	0.47	0.25	-0.87	-0.26	0.36		0.23	0.23	0.66	0.33	0.46	0.35	0.07	0.31	0.39	0.3	0.67	0.46	0.46	-0.74	0.62	0.32	0.51
Non Current Assets Total	0.63	0.5	0.73	0.06	0.99	-0.02	-0.93	0.73	0.23		0.18	0.38	0.65	0.94	0.8	0.68	0.96	0.85	0.91	0.5	0.94	-0.22	-0.48	-0.35	0.95	0.19
Other Assets	0.36	-0.06	0.12	0.63	0.1	0.08	0.08	0.39	0.23	0.18		0.37	-0.24	0.24	-0.27	0.21	0.05	-0.19	-0.04	0.35	0.1	0.55	-0.67	0.11	0.09	0.6
Cash And Short Term Investments	0.95	0.14	0.41	0.84	0.37	-0.46	-0.38	0.43	0.66	0.38	0.37		0.04	0.66	0.39	0.56	0.51	0.42	0.23	0.99	0.53	0.3	-0.78	0.29	0.29	0.88
Net Receivables	0.21	0.27	0.5	-0.35	0.69	-0.29	-0.69	0.34	0.33	0.65	-0.24	0.04		0.59	0.72	-0.02	0.69	0.74	0.91	0.13	0.78	-0.25	-0.11	-0.15	0.79	-0.2
Common Stock Total Equity	0.84	0.41	0.7	0.33	0.94	-0.24	-0.91	0.7	0.46	0.94	0.24	0.66	0.59		0.82	0.71	0.97	0.85	0.84	0.75	0.97	-0.11	-0.65	-0.18	0.88	0.45
Non Current Liabilities Total	0.58	0.43	0.66	-0.13	0.85	-0.32	-0.93	0.5	0.35	0.8	-0.27	0.39	0.72	0.82		0.59	0.9	0.99	0.85	0.5	0.86	-0.42	-0.22	-0.22	0.83	-0.01
Other Current Assets	0.69	0.43	0.5	0.33	0.67	0.1	-0.67	0.54	0.07	0.68	0.21	0.56	-0.02	0.71	0.59		0.69	0.59	0.37	0.62	0.55	-0.2	-0.41	-0.3	0.51	0.36
Other Stockholder Equity	0.72	0.49	0.71	0.12	0.97	-0.14	-0.97	0.66	0.31	0.96	0.05	0.51	0.69	0.97	0.9	0.69		0.92	0.91	0.61	0.97	-0.28	-0.44	-0.3	0.92	0.25
Total Liab	0.61	0.51	0.76	-0.1	0.89	-0.31	-0.93	0.57	0.39	0.85	-0.19	0.42	0.74	0.85	0.99	0.59	0.92		0.88	0.52	0.89	-0.31	-0.28	-0.18	0.87	0.02
Property Plant And Equipment Gross	0.46	0.43	0.67	-0.16	0.93	-0.17	-0.9	0.59	0.3	0.91	-0.04	0.23	0.91	0.84	0.85	0.37	0.91	0.88		0.35	0.94	-0.28	-0.31	-0.29	0.95	-0.01
Total Current Assets	0.98	0.21	0.51	0.78	0.49	-0.45	-0.51	0.51	0.67	0.5	0.35	0.99	0.13	0.75	0.5	0.62	0.61	0.52	0.35		0.63	0.24	-0.78	0.22	0.41	0.84
Common Stock	0.72	0.4	0.7	0.15	0.95	-0.27	-0.92	0.65	0.46	0.94	0.1	0.53	0.78	0.97	0.86	0.55	0.97	0.89	0.94	0.63		-0.17	-0.55	-0.19	0.93	0.29
Short Long Term Debt Total	0.17	0.05	0.1	0.5	-0.27	-0.22	0.39	0.05	0.46	-0.22	0.55	0.3	-0.25	-0.11	-0.42	-0.2	-0.28	-0.31	-0.28	0.24	-0.17		-0.5	0.68	-0.17	0.47
Common Stock Shares Outstanding	-0.78	0.02	-0.38	-0.76	-0.44	0.46	0.31	-0.55	-0.74	-0.48	-0.67	-0.78	-0.11	-0.65	-0.22	-0.41	-0.44	-0.28	-0.31	-0.78	-0.55	-0.5		-0.31	-0.42	-0.8
Short Term Debt	0.12	-0.05	0.03	0.31	-0.35	-0.71	0.34	-0.07	0.62	-0.35	0.11	0.29	-0.15	-0.18	-0.22	-0.3	-0.3	-0.18	-0.29	0.22	-0.19	0.68	-0.31		-0.28	0.27
Property Plant Equipment	0.53	0.45	0.73	-0.08	0.96	-0.12	-0.91	0.63	0.32	0.95	0.09	0.29	0.79	0.88	0.83	0.51	0.92	0.87	0.95	0.41	0.93	-0.17	-0.42	-0.28		0.06
Net Tangible Assets	0.79	-0.05	0.16	0.99	0.14	-0.25	-0.09	0.34	0.51	0.19	0.6	0.88	-0.2	0.45	-0.01	0.36	0.25	0.02	-0.01	0.84	0.29	0.47	-0.8	0.27	0.06

Click cells to compare fundamentals

Adaptimmune Therapeutics Account Relationship Matchups

Adaptimmune Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	451.1M	469.5M	328.9M	282.6M	325.0M	268.1M
Other Current Liab	24.3M	27.6M	30.8M	28.9M	33.2M	20.9M
Total Current Liabilities	39.1M	62.5M	64.5M	72.8M	83.7M	44.6M
Total Stockholder Equity	341.2M	206.0M	81.9M	39.5M	45.4M	43.2M
Property Plant And Equipment Net	46.7M	51.4M	71.5M	71.7M	82.5M	86.6M
Net Debt	(33.2M)	(124.5M)	(85.0M)	(118.8M)	(106.9M)	(112.2M)
Retained Earnings	(585.8M)	(743.8M)	(909.3M)	(1.0B)	(920.9M)	(874.8M)
Accounts Payable	6.4M	8.1M	4.8M	8.1M	9.3M	5.5M
Cash	56.9M	149.9M	108.0M	144.0M	165.6M	112.8M
Non Current Assets Total	53.0M	54.1M	73.5M	75.1M	86.3M	90.6M
Other Assets	7.0M	4.6M	1.7M	1.6M	1.8M	1.7M
Cash And Short Term Investments	368.2M	369.6M	204.6M	146.9M	169.0M	202.8M
Net Receivables	139K	752K	7.4M	46.9M	54.0M	56.7M
Common Stock Total Equity	939K	943K	1.3M	1.3M	1.5M	1.6M
Liabilities And Stockholders Equity	451.1M	469.5M	328.9M	282.6M	325.0M	268.1M
Non Current Liabilities Total	70.8M	201.0M	182.5M	170.3M	195.9M	205.7M
Other Current Assets	34.0M	54.2M	51.5M	13.7M	15.7M	21.1M
Other Stockholder Equity	935.7M	959.6M	990.7M	1.1B	1.2B	1.3B
Total Liab	109.9M	263.6M	247.0M	243.1M	279.6M	293.5M
Property Plant And Equipment Gross	46.7M	51.4M	71.5M	130.9M	150.6M	158.1M
Total Current Assets	398.2M	415.5M	255.4M	207.6M	238.7M	229.0M
Accumulated Other Comprehensive Income	(10.0M)	(11.1M)	(875K)	(3.7M)	(3.4M)	(3.2M)
Common Stock	1.3M	1.3M	1.4M	1.9M	2.1M	2.3M
Short Long Term Debt Total	23.7M	25.5M	23.1M	25.2M	22.7M	38.5M
Common Stock Shares Outstanding	142.5M	155.8M	161.2M	201.1M	181.0M	129.5M
Short Term Debt	5.5M	4.6M	5.5M	4.0M	3.6M	4.6M
Property Plant Equipment	31.1M	27.8M	30.5M	71.5M	82.3M	86.4M
Net Tangible Assets	121.4M	339.5M	205.0M	81.4M	93.7M	89.0M
Non Currrent Assets Other	4.6M	1.7M	1.6M	3.0M	2.7M	3.6M
Short Term Investments	311.3M	219.6M	96.6M	2.9M	3.4M	3.2M
Other Liab	598K	49.9M	177.9M	162.2M	186.5M	195.8M
Current Deferred Revenue	2.8M	22.2M	23.5M	29.0M	33.3M	21.0M
Inventory	2.1M	746K	1.3M	1.3M	1.5M	1.4M
Intangible Assets	1.7M	1M	442K	330K	379.5K	360.5K
Capital Surpluse	574.2M	585.6M	935.7M	959.6M	1.1B	657.5M
Retained Earnings Total Equity	(318.5M)	(455.7M)	(585.8M)	(743.8M)	(669.5M)	(636.0M)
Non Current Liabilities Other	70.8M	201.0M	1.3M	1.4M	1.6M	1.5M
Net Invested Capital	341.2M	206.0M	81.9M	39.5M	35.6M	33.8M
Net Working Capital	359.1M	352.9M	190.9M	134.8M	155.0M	233.6M
Capital Stock	1.3M	1.3M	1.4M	1.9M	2.1M	1.4M

Pair Trading with Adaptimmune Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Adaptimmune Stock

0.77	DNLI	Denali Therapeutics	Pair Corr
0.83	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr

Moving against Adaptimmune Stock

0.82	LFCR	Lifecore Biomedical	Pair Corr
0.64	GILD	Gilead Sciences	Pair Corr
0.62	BMY	Bristol Myers Squibb	Pair Corr
0.32	IMCC	Im Cannabis Corp	Pair Corr

The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.

The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Adaptimmune Stock Analysis

When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC